MCID: KPS004
MIFTS: 73

Kaposi Sarcoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Blood diseases, Neuronal diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 53 12 72 49 55 51 40 69
Kaposi's Sarcoma 12 49 36 14
Angiofollicular Ganglionic Hyperplasia 55 69
Kaposi Sarcoma, Susceptibility to 53 13
Kaposi's Sarcoma of Soft Tissue 12 69
Kaposi's Sarcoma of Palate 12 69
Kaposi's Sarcoma of Lung 12 69
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 53
Multiple Idiopathic Pigmented Hemangiosarcoma 53
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Multicentric Giant Lymph Node Hyperplasia 55
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Lymphadenopathic Kaposi's Sarcoma 12
Angiofollicular Lymph Hyperplasia 55
Multi-Centric Castleman's Disease 69
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 49
Non-Aids-Related Kaposi Sarcoma 69
Multicentric Castleman Disease 55
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 49
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 49
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 69
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 49
Castleman Disease 55
Sarcoma, Kaposi 41
Hhv8 49
Kshv 49
Mcd 55

Characteristics:

Orphanet epidemiological data:

55
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 49 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). The main aim is to restore immunity. Last updated: 2/4/2016

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to acquired immunodeficiency syndrome and hepatitis, and has symptoms including fatigue, fever and diarrhea. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi's sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Doxil and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are hematopoietic system and cellular

OMIM : 53 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

MedlinePlus : 40 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS Medicines. NIH: National Cancer Institute

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results_in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

Wikipedia : 72 Kaposi\'s sarcoma (KS) is a type of cancer that can form in the skin, lymph nodes, or other organs. The... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 31.1 IFNA1 IFNA2 IL6 TP53
2 hepatitis 30.6 IFNA1 IFNA2 IRF3 IRF7
3 hepatitis c 29.9 IFNA1 IFNA2 IFNB1 IRF3 IRF7
4 rheumatoid arthritis 29.6 CXCL1 ICAM1 IL6 IL6ST VEGFA
5 molluscum contagiosum 29.4 CASP8 CCR8 IFNB1
6 human immunodeficiency virus type 1 28.6 CASP8 CCR3 CXCL1 IFNA1 IL6 IRF3
7 angiofollicular lymph hyperplasia 12.3
8 endemic kaposi sarcoma 12.3
9 colon kaposi sarcoma 12.1
10 immunodeficiency 16 12.0
11 human herpesvirus 8 11.9
12 malonyl-coa decarboxylase deficiency 11.8
13 macular dystrophy, corneal 11.8
14 multiple carboxylase deficiency 11.8
15 rectum kaposi's sarcoma 11.1
16 sarcoma 11.0
17 plantar wart 10.7 IFNA1 TP53
18 macular retinal edema 10.6 ICAM1 IL6 VEGFA
19 oral erosive lichen 10.6 IFNA1 IFNB1
20 lymphomatoid granulomatosis 10.6 IFNA1 IFNA2
21 nodular goiter 10.6 ICAM1 IL6 VEGFA
22 pericardial effusion 10.6 FGF2 IL6 VEGFA
23 limb ischemia 10.6 FGF2 IL6 VEGFA
24 microvascular complications of diabetes 1 10.5 FGF2 ICAM1 VEGFA
25 diabetic macular edema 10.5 FGF2 ICAM1 IL6 VEGFA
26 squamous papillomatosis 10.5 IFNA1 IFNA2
27 breast carcinoma in situ 10.5 FGF2 IL6 TP53 VEGFA
28 endometrial adenocarcinoma 10.5 FGF2 TP53 VEGFA
29 microvascular complications of diabetes 5 10.5 FGF2 ICAM1 VEGFA
30 pediatric lymphoma 10.5 IRF3 IRF7
31 newcastle disease 10.4 IFNA1 IFNB1 IRF3
32 critical limb ischemia 10.4 IL6 VEGFA
33 mouth disease 10.4 IFNA1 IL6 IRF3
34 melanoma, cutaneous malignant 1 10.4 CDK6 IFNA2 TP53
35 relapsing-remitting multiple sclerosis 10.4 ICAM1 IFNA1 IFNB1 IL6
36 squamous cell carcinoma, head and neck 10.4 CDK6 FGF2 TP53 VEGFA
37 severe acute respiratory syndrome 10.4 IFNA1 IFNB1 IRF3
38 arteries, anomalies of 10.4 ICAM1 IL6 VEGFA
39 lymphoma 10.4
40 castleman disease 10.4
41 multicentric castleman disease 10.4
42 kidney cancer 10.4 FGF2 IFNA1 IFNA2 TP53 VEGFA
43 gastrointestinal system cancer 10.4 IL6 TP53 VEGFA
44 keratitis, hereditary 10.4 CXCL1 FGF2 VEGFA
45 primary effusion lymphoma 10.3
46 la crosse encephalitis 10.3 CXCL1 IFNB1 IRF3
47 esophagitis 10.2 CCR3 IL6 TP53
48 vitreous disease 10.2 FGF2 PDGFB VEGFA
49 endotheliitis 10.2
50 viral infectious disease 10.1 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Symptoms via clinical synopsis from OMIM:

53
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema


Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

55 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 55 31 occasional (7.5%) Occasional (29-5%) HP:0012378
2 fever 55 31 occasional (7.5%) Occasional (29-5%) HP:0001945
3 diarrhea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002014
4 immunodeficiency 55 31 frequent (33%) Frequent (79-30%) HP:0002721
5 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
6 lymphedema 55 31 occasional (7.5%) Occasional (29-5%) HP:0001004
7 abnormality of the spleen 55 31 frequent (33%) Frequent (79-30%) HP:0001743
8 neoplasm of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0008069
9 skin rash 55 31 occasional (7.5%) Occasional (29-5%) HP:0000988
10 venous insufficiency 55 31 occasional (7.5%) Occasional (29-5%) HP:0005293
11 hypermelanotic macule 55 31 hallmark (90%) Very frequent (99-80%) HP:0001034
12 papule 55 31 frequent (33%) Frequent (79-30%) HP:0200034
13 abnormality of the gastrointestinal tract 55 31 frequent (33%) Frequent (79-30%) HP:0011024
14 abnormality of the liver 55 31 occasional (7.5%) Occasional (29-5%) HP:0001392
15 encephalopathy 55 31 frequent (33%) Frequent (79-30%) HP:0001298
16 abnormality of the lower limb 55 31 hallmark (90%) Very frequent (99-80%) HP:0002814
17 skin nodule 55 31 frequent (33%) Frequent (79-30%) HP:0200036
18 skin plaque 55 31 occasional (7.5%) Occasional (29-5%) HP:0200035
19 hemangioma 55 31 frequent (33%) Frequent (79-30%) HP:0001028
20 lymphoproliferative disorder 55 31 frequent (33%) Frequent (79-30%) HP:0005523
21 generalized lymphadenopathy 55 31 frequent (33%) Frequent (79-30%) HP:0008940
22 susceptibility to herpesvirus 55 31 obligate (100%) Obligate (100%) HP:0005353
23 edema 31 HP:0000969
24 macule 55 Very frequent (99-80%)
25 neoplasm 31 HP:0002664
26 abnormality of lung morphology 55 Occasional (29-5%)
27 abnormality of the retina 55 Frequent (79-30%)
28 neoplasm by anatomical site 55 Occasional (29-5%)
29 abnormal retinal morphology 31 frequent (33%) HP:0000479
30 abnormal lung morphology 31 occasional (7.5%) HP:0002088

UMLS symptoms related to Kaposi Sarcoma:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 ICAM1 CASP8 IFNB1 CCR3 IL6 CDK6
2 cellular MP:0005384 10.23 FGF4 ICAM1 CASP8 CCR3 IL6 CDK6
3 homeostasis/metabolism MP:0005376 10.22 ICAM1 CASP8 IFNB1 CCR3 IL6 FGF2
4 immune system MP:0005387 10.21 IRF3 ICAM1 CASP8 IFNB1 CCR3 IL6
5 integument MP:0010771 9.92 IL6ST ICAM1 CASP8 IL6 TP53 VEGFA
6 liver/biliary system MP:0005370 9.8 CASP8 IL6 CDK6 IL6ST TP53 VEGFA
7 muscle MP:0005369 9.76 ICAM1 CASP8 IL6 CDK6 FGF2 TP53
8 neoplasm MP:0002006 9.65 ICAM1 CASP8 IFNB1 IL6 CDK6 IL6ST
9 vision/eye MP:0005391 9.23 ICAM1 IL6 IL6ST FGF2 TP53 VEGFA

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 45 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxol 17 45 PACLITAXEL Bristol-Myers Squibb August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
5
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
7
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
12
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
14 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
21 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
23 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
25 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
26 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
27 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
28
Tenofovir Phase 4,Phase 3 147127-20-6 464205
29 Ganciclovir triphosphate Phase 4,Phase 2
30
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
33
Zidovudine Approved Phase 2, Phase 3, Phase 1 30516-87-1 35370
34
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
35
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
36
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Analgesics Phase 3,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
44 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1
47 Cyclooxygenase 2 Inhibitors Phase 3
48 Cyclooxygenase Inhibitors Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Albumin-Bound Paclitaxel Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 164)

# Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
4 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
8 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
10 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
11 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
13 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
14 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
16 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
17 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Recruiting NCT01435018 Phase 3 Coformulated EFV/FTC/TDF;Etoposide;Bleomycin and Vincristine (BV);Paclitaxel (PTX)
18 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
19 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
20 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
21 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
22 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
23 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
24 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
25 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
26 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
27 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
28 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
29 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
30 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
31 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
32 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
33 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
34 Suppression of Oral HHV8 Shedding With Valganciclovir Completed NCT00194467 Phase 2 valganciclovir;placebo
35 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma Completed NCT00019123 Phase 2 thalidomide
36 Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection Completed NCT00019240 Phase 2 cidofovir
37 Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2 indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate
38 Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00020449 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
39 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002188 Phase 2 Alitretinoin
40 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
41 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
42 The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
43 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
44 SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment Completed NCT00005931 Phase 2 SU5416
45 The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2 Interferon alfa-2b;Didanosine
46 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin
47 A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00000996 Phase 2 Doxorubicin hydrochloride
48 A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma Completed NCT00002314 Phase 2 Ro 24-7429
49 Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Completed NCT00002189 Phase 2 Paclitaxel
50 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy Completed NCT00000807 Phase 2 Etoposide

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

38
Skin, Lymph Node, Lung, Prostate, Liver, Heart, Testes

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 399)
# Title Authors Year
1
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
2
Rubbery purple and red lesions in the GI tract: A Case of GI tract Kaposi Sarcoma. ( 29306041 )
2018
3
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
4
Age of Infection with Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. ( 29369149 )
2018
5
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. ( 29282751 )
2018
6
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
7
Kaposi sarcoma in an immunosuppressed young woman. ( 29398005 )
2018
8
As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. ( 29365083 )
2018
9
Role of Radiotherapy in Mucosal Kaposi Sarcoma. ( 29383006 )
2018
10
Kaposi sarcoma presenting shortly after primary infection by HIV and human herpesvirus-8. ( 29256918 )
2018
11
Kaposi Sarcoma After Allogeneic Hematopoietic Stem Cell Transplant: A Rare Complication. ( 29292681 )
2018
12
Oral Kaposi Sarcoma in HIV-seronegative Saudi patient: Literature review and case report. ( 28725131 )
2017
13
Classic Kaposi Sarcoma: An Exceptional Cause of Adrenal Incidentaloma. ( 29264526 )
2017
14
Kaposi Sarcoma in an Human Immunodeficiency Virus (HIV)-Seronegative Mediterranean Female: Report of a Rare Case. ( 28743856 )
2017
15
Diagnosis and Treatment of Kaposi Sarcoma. ( 28324233 )
2017
16
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden-Reply. ( 28662223 )
2017
17
Successful Treatment of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations With the Human Herpesvirus 8 miRNome and Specific T Cell Response. ( 28489271 )
2017
18
Kaposi sarcoma herpesvirus pathogenesis. ( 28893942 )
2017
19
Treatment of cutaneous iatrogenic Kaposi sarcoma with topical timolol. ( 28853153 )
2017
20
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
21
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. ( 28216610 )
2017
22
Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. ( 27986137 )
2017
23
Clinical and Endoscopic Features of Gastrointestinal Kaposi Sarcoma: A Single-Center Portuguese Experience over the Last Decade. ( 29255756 )
2017
24
Epigenetic manipulation of host chromatin by Kaposi sarcoma-associated herpesvirus: a tumor-promoting factor? ( 28802146 )
2017
25
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
26
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden. ( 28662221 )
2017
27
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
28
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. ( 28157730 )
2017
29
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. ( 28424322 )
2017
30
Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome. ( 29239932 )
2017
31
Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy. ( 28837714 )
2017
32
Enhanced phosphorylation of sphingosine and ceramide sustains the exuberant proliferation of endothelial progenitors in Kaposi sarcoma. ( 29345349 )
2017
33
Kaposi sarcoma: An unconventional cause of lower extremity lymphedema. ( 28875759 )
2017
34
An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus. ( 28872106 )
2017
35
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. ( 28881567 )
2017
36
Maxillary Sinus Kaposi Sarcoma: Case Report in an HIV-Negative Patient with Thymoma. ( 29204303 )
2017
37
Oral Localization of Kaposi Sarcoma: Clinical Presentation and Conservative Management. ( 28708648 )
2017
38
Is acquired arterial-venous fistula related to Kaposi sarcoma? ( 28214029 )
2017
39
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
40
Hepatic Kaposi sarcoma: A case report and review of the literature. ( 28217255 )
2017
41
Murine Gammaherpesvirus 68 Expressing Kaposi Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen (LANA) Reveals both Functional Conservation and Divergence in LANA Homologs. ( 28747501 )
2017
42
Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. ( 28077522 )
2017
43
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. ( 28488400 )
2017
44
Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. ( 28531260 )
2017
45
Acquired Immune Deficiency Syndrome-Associated Kaposi Sarcoma in a Child Presenting as a Solitary Plantar Hyperkeratotic Plaque. ( 28288525 )
2017
46
High-dose-rate brachytherapy in the treatment of skin Kaposi sarcoma. ( 29441101 )
2017
47
mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi Sarcoma. ( 28506734 )
2017
48
Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. ( 29272148 )
2017
49
The pattern of secondary cancers in patients with Kaposi sarcoma in the United States. ( 28900786 )
2017
50
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. ( 28430817 )
2017

Variations for Kaposi Sarcoma

Cosmic variations for Kaposi Sarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 68
2 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 67
3 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 6
4 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 6

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

36
# Name Kegg Source Accession
1 Kaposi's sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CASP8 CXCL1 FGF2 FGF4 ICAM1 IFNA1
2
Show member pathways
13.9 CASP8 FGF2 FGF4 IFNA1 IFNA2 IFNB1
3
Show member pathways
13.85 CASP8 CCR3 CCR8 CDK6 CXCL1 FGF2
4
Show member pathways
13.66 CASP8 CCR3 CCR8 CXCL1 IFNA1 IFNA2
5
Show member pathways
13.57 FGF2 FGF4 ICAM1 IFNA1 IFNA2 IFNB1
6
Show member pathways
13.45 CCR3 CCR8 CXCL1 FGF2 FGF4 IL6
7
Show member pathways
13.35 CASP8 CCR3 CCR8 CXCL1 FGF2 FGF4
8
Show member pathways
13.35 IFNA1 IFNA2 IFNB1 IRF3 IRF7 PDGFB
9
Show member pathways
13.11 CXCL1 FGF2 FGF4 ICAM1 IFNA1 IFNA2
10
Show member pathways
13.1 CDK6 FGF2 FGF4 IL6 PDGFB TP53
11
Show member pathways
12.99 CASP8 CXCL1 IFNA1 IFNA2 IFNB1 IL6
12
Show member pathways
12.9 CASP8 ICAM1 IFNA1 IFNA2 IL6 VEGFA
13 12.81 CASP8 FGF2 FGF4 PDGFB TP53 VEGFA
14
Show member pathways
12.76 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
15 12.72 CASP8 CDK6 FGF2 FGF4 IFNA1 IFNA2
16
Show member pathways
12.71 CASP8 CDK6 ICAM1 IFNA1 IFNA2 IFNB1
17
Show member pathways
12.62 CXCL1 FGF2 IL6 PDGFB TP53
18
Show member pathways
12.58 ICAM1 IFNA1 IFNA2 IFNB1 IRF3 IRF7
19
Show member pathways
12.56 CASP8 IFNA1 IFNA2 IFNB1 IL6 IRF3
20
Show member pathways
12.56 CASP8 CDK6 FGF2 FGF4 IFNA1 IFNA2
21 12.43 ICAM1 IL6 PDGFB TP53
22
Show member pathways
12.39 IFNA1 IFNA2 IFNB1 IL6 IL6ST PDGFB
23
Show member pathways
12.35 CASP8 CXCL1 IL6 IL6ST
24
Show member pathways
12.32 IFNA1 IFNA2 IFNB1 IL6
25
Show member pathways
12.29 IFNB1 IL6 IRF3 IRF7
26 12.28 CASP8 IFNA1 IFNA2 IFNB1 IL6
27 12.27 CASP8 CCR3 CCR8 CDK6 IL6ST IRF3
28
Show member pathways
12.25 CASP8 IFNA1 IFNA2 IFNB1
29 12.18 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
30
Show member pathways
12.16 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
31 12.13 ICAM1 PDGFB TP53 VEGFA
32 12.12 FGF2 FGF4 IL6 PDGFB VEGFA
33 12.09 IFNA1 IFNA2 IFNB1 IRF3 IRF7 TP53
34
Show member pathways
12.07 CASP8 CCR3 CCR8 CDK6 CXCL1 FGF2
35 12.06 CXCL1 ICAM1 IL6 TP53
36 12.03 FGF2 ICAM1 IL6 TP53 VEGFA
37 12.01 CASP8 CXCL1 ICAM1 IL6
38 11.95 FGF2 FGF4 IL6 PDGFB
39 11.94 CXCL1 IFNB1 IL6 IL6ST IRF7 TP53
40
Show member pathways
11.92 CXCL1 ICAM1 IL6 IL6ST
41 11.91 IFNA1 IFNA2 IFNB1 IL6 IL6ST
42 11.9 CXCL1 ICAM1 IL6 VEGFA
43 11.84 FGF2 FGF4 PDGFB VEGFA
44 11.81 ICAM1 IL6 TP53
45 11.76 IFNA2 IFNB1 IL6
46 11.72 CCR3 FGF2 IL6 PDGFB
47
Show member pathways
11.69 ICAM1 IL6 VEGFA
48 11.62 CASP8 CXCL1 IL6
49 11.59 IL6 TP53 VEGFA
50 11.57 CXCL1 ICAM1 IL6

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CXCL1 FGF2 FGF4 IFNA1 IFNA2 IFNB1
2 extracellular space GO:0005615 9.61 CXCL1 FGF2 ICAM1 IFNA1 IFNA2 IFNB1
3 interleukin-6 receptor complex GO:0005896 8.62 IL6 IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 FGF2 FGF4 ICAM1 PDGFB
2 response to lipopolysaccharide GO:0032496 9.96 CASP8 CXCL1 ICAM1 IRF3
3 chemotaxis GO:0006935 9.94 CCR3 CCR8 CXCL1 FGF2
4 cytokine-mediated signaling pathway GO:0019221 9.93 IFNA1 IFNA2 IL6 IL6ST
5 defense response GO:0006952 9.92 CXCL1 IFNA1 IFNA2 IFNB1
6 viral process GO:0016032 9.91 CASP8 CCR3 ICAM1 IL6ST IRF3 IRF7
7 chemokine-mediated signaling pathway GO:0070098 9.85 CCR3 CCR8 CXCL1
8 interferon-gamma-mediated signaling pathway GO:0060333 9.85 ICAM1 IRF3 IRF7
9 B cell differentiation GO:0030183 9.84 IFNA1 IFNA2 IFNB1
10 positive regulation of MAP kinase activity GO:0043406 9.83 FGF2 PDGFB VEGFA
11 positive chemotaxis GO:0050918 9.79 FGF2 PDGFB VEGFA
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.78 FGF2 PDGFB VEGFA
13 positive regulation of endothelial cell proliferation GO:0001938 9.78 CCR3 FGF2 PDGFB VEGFA
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNA2 IL6 IL6ST VEGFA
15 B cell proliferation GO:0042100 9.74 IFNA1 IFNA2 IFNB1
16 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.73 CASP8 IRF3 IRF7
17 humoral immune response GO:0006959 9.73 IFNA1 IFNA2 IFNB1 IL6
18 regulation of type I interferon-mediated signaling pathway GO:0060338 9.72 IFNA1 IFNA2 IFNB1
19 positive regulation of cell division GO:0051781 9.71 FGF2 FGF4 PDGFB VEGFA
20 T cell activation involved in immune response GO:0002286 9.7 IFNA1 IFNA2 IFNB1
21 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.69 IFNA1 IFNA2 IFNB1
22 positive regulation of acute inflammatory response GO:0002675 9.68 IL6 IL6ST
23 positive regulation of interferon-alpha production GO:0032727 9.68 IRF3 IRF7
24 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.68 IRF3 IRF7
25 interleukin-6-mediated signaling pathway GO:0070102 9.67 IL6 IL6ST
26 natural killer cell activation involved in immune response GO:0002323 9.67 IFNA1 IFNA2 IFNB1
27 negative regulation of T cell differentiation GO:0045581 9.65 IFNA2 IFNB1
28 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 ICAM1 IL6 PDGFB TP53 VEGFA
29 chondroblast differentiation GO:0060591 9.64 FGF2 FGF4
30 defense response to virus GO:0051607 9.63 IFNA1 IFNA2 IFNB1 IL6 IRF3 IRF7
31 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNA2 IFNB1
32 response to exogenous dsRNA GO:0043330 9.62 IFNA1 IFNA2 IFNB1 IRF3
33 type I interferon biosynthetic process GO:0045351 9.59 IRF3 IRF7
34 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.58 FGF2 FGF4
35 MDA-5 signaling pathway GO:0039530 9.58 IRF3 IRF7
36 type I interferon signaling pathway GO:0060337 9.35 IFNA1 IFNA2 IFNB1 IRF3 IRF7
37 regulation of receptor activity GO:0010469 9.28 CXCL1 FGF2 FGF4 IFNA1 IFNA2 IFNB1
38 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 FGF2 FGF4 IFNB1 IL6 IRF3 IRF7
39 positive regulation of transcription, DNA-templated GO:0045893 10.11 FGF2 IFNA2 IL6 IRF7 PDGFB TP53
40 negative regulation of apoptotic process GO:0043066 10.09 FGF4 IL6 IL6ST TP53 VEGFA
41 positive regulation of cell proliferation GO:0008284 10.08 FGF2 FGF4 IL6 IL6ST PDGFB VEGFA
42 positive regulation of gene expression GO:0010628 10.04 FGF4 IL6 PDGFB TP53 VEGFA

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 FGF2 FGF4 PDGFB
2 chemoattractant activity GO:0042056 9.5 FGF2 PDGFB VEGFA
3 C-C chemokine receptor activity GO:0016493 9.43 CCR3 CCR8
4 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
5 growth factor activity GO:0008083 9.43 CXCL1 FGF2 FGF4 IL6 PDGFB VEGFA
6 interleukin-6 receptor binding GO:0005138 9.37 IL6 IL6ST
7 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
8 cytokine activity GO:0005125 9.17 CXCL1 FGF2 IFNA1 IFNA2 IFNB1 IL6

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....